Last reviewed · How we verify
Dexmedetomidine administered intranasally
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Procedural sedation via intranasal administration, Acute anxiety or agitation management.
At a glance
| Generic name | Dexmedetomidine administered intranasally |
|---|---|
| Sponsor | First Affiliated Hospital of Chongqing Medical University |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Sedation |
| Phase | Phase 3 |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, which are distributed throughout the brain and spinal cord. This activation leads to decreased norepinephrine release and reduced neuronal firing, resulting in sedative and analgesic effects. The intranasal route provides non-invasive delivery for rapid onset of action, potentially useful for procedural sedation or acute anxiety management.
Approved indications
- Procedural sedation via intranasal administration
- Acute anxiety or agitation management
Common side effects
- Hypotension
- Bradycardia
- Dry mouth
- Sedation/drowsiness
- Rebound hypertension
Key clinical trials
- Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients (PHASE4)
- The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder (NA)
- Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Undergoing Cataract Surgery (PHASE3)
- Intranasal Dexmedetomidine, Ketamine or Midazolam for Anxiety and Respiratory Complications in Children (NA)
- Effect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain (PHASE4)
- Effectiveness of Intranasal Dexmedetomidine Premedication in Child Intubation (PHASE3)
- Effects of Nasal Administration of Dexmedetomidine on Pre-anesthesia Sedation, Intraoperative Brain Electrical Activity, and Incidence of Agitation During Recovery in Children (PHASE4)
- Clinical Study of Dexmedetomidine Administered Intranasally to Relieve Perioperative Anxiety and Depression in Patients With Colorectal Tumors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: